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a b s t r a c t
Heme oxygenase (Hmox) is an endogenous system that offers protection against placental
cytotoxic damage associated with preeclampsia. The Hmox1/carbon monoxide (CO) path-
way inhibits soluble Flt-1 (sFlt-1) and soluble Endoglin (sEng). More importantly, statins
induce Hmox1 and suppress the release of sFlt-1 and sEng; thus, statins and Hmox1 acti-
vators are potential novel therapeutic agents for treating preeclampsia. The contribution
of the Hmox system to the pathogenesis of preeclampsia has been further indicated by
the incidence of preeclampsia being reduced by a third in smokers, who had reduced lev-
els of circulating sFlt-1. Interestingly, preeclamptic women exhale less CO compared with
womenwithhealthypregnancies.Hmox1 is reducedprior to the increase in sFlt-1asHmox1
mRNA expression in the trophoblast is decreased in the ﬁrst trimester in women who go
on to develop preeclampsia. Induction of Hmox1 or exposure to CO or bilirubin has been
shown to inhibit the release of sFlt-1 and sEng in animal models of preeclampsia. The func-
tional beneﬁt of statins and Hmox1 induction in women with preeclampsia is valid not
only because they inhibit sFlt-1 release, but also because statins and Hmox1 are associ-
ated with anti-apoptotic, anti-inﬂammatory, and anti-oxidant properties. The StAmP trial
is the ﬁrst randomized control trial (RCT) evaluating the use of pravastatin to ameliorate
severe preeclampsia. This proof-of-concept study will pave the way for future global RCT,
the success of which will greatly contribute to achieving the United Nations Millennium
Development Goals (MDG4 and MDG5) and offering an affordable and easily accessible
therapy for preeclampsia.
he Auth© 2014 T
. Introduction
Preeclampsia is characterized by the de novo onset of
ypertension and proteinuria after 20 weeks of gestation.
f left untreated it can lead to debilitating and poten-
ially eclamptic seizures that can cause coma and even
eath. According to the Preeclampsia Foundation, globally
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preeclampsia accounts for 76,000 maternal deaths and
500,000 infant deaths every year. Currently, the lack of
effective pharmacological options to treat preeclampsia
indicates that there is an unmet need for an affordable and
easily accessible treatment to prevent maternal and infant
mortality. Factors originating in the placenta are likely to
be responsible for the condition, yet the exact etiology
of the disorder is unknown. Currently, the only curative
management strategy is the premature termination of
pregnancy and the delivery of the placenta. Compelling
Open access under CC BY license.data have pointed to maternal endothelial dysfunction as
the central phenomenon responsible for the clinical signs
of the disorder–hypertension and proteinuria (Roberts
et al., 1989). Theories that have been proposed to cause
er CC BY license.
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Fig. 1. A schematic diagram of the heme oxygenase pathway.154 W. Ramma, A. Ahmed / Journal of Repro
endothelial dysfunction include poor placental vascular
remodeling, oxidative stress (Roberts and Redman, 1993),
excessive inﬂammation (Redman et al., 1999), and an
imbalance in angiogenic factors (Ahmed, 1997). Among
these, the imbalance in anti-angiogenic factors has
emerged as the one phenomenon that is most strongly
associated with the clinical signs of preeclampsia and
disease severity (Ahmed, 1997; Maynard et al., 2003;
Venkatesha et al., 2006; Levine et al., 2005). In contrast, the
elevation in inﬂammatory status observed in preeclampsia
does not precede the onset of the disorder (Djurovic et al.,
2002; Kronborg et al., 2011). In addition, an increase
in inﬂammation is not associated with the increase in
anti-angiogenic factors (Ramma et al., 2012) or disease
severity (Ozler et al., 2012). Together, these do indeed
indicate that the increase in inﬂammation occurs as a
consequence of preeclampsia and that it is not the cause
of the disorder (Ramma and Ahmed, 2011). To date, it
seems that therapeutic strategies aimed at addressing the
angiogenic imbalance in preeclampsia will provide the
most promising outcome.
2. Angiogenic growth factors in the placenta
The human placenta is a rich source of angiogenic
growth factors. Indeed, numerous studies have demon-
strated the expression and localization of various vascular
growth factors and their receptors in the placenta (Sharkey
et al., 1993; Charnock-Jones et al., 1994; Ahmed et al.,
1995; Kilby et al., 1996; Khaliq et al., 1996, 1999; Dunk
and Ahmed, 2001). However, the ﬁnding that vascular
endothelial growth factor (VEGF) stimulates nitric oxide
release from trophoblasts and endothelial cells via the
VEGF receptor-1 (Flt-1) (Ahmed, 1997) has led to a new
approach to tackling preeclampsia.
Vascular endothelial growth factor (VEGF) is known
to maintain endothelial cell integrity (Deanﬁeld et al.,
2007). The antagonist of VEGF, soluble Flt-1, binds to free
VEGFandplacental growth factor (PlGF) sequestering them
and disrupting their proper signaling. The hypothesis that
preeclampsiamight arise because of the loss of VEGF activ-
ity as a result of the “increase in the levels of endogenous
soluble Flt-1 that may antagonize the beneﬁcial effects of
VEGF” was ﬁrst proposed in a review in 1997 (Ahmed,
1997). In recent years, clinical studies have shown that sev-
eral weeks prior to the onset of preeclampsia, the levels of
the anti-angiogenic factors, sFlt-1 (Levine et al., 2004) and
sEng (Venkatesha et al., 2006) are elevated in the maternal
circulation. Additionally, thematernal PlGF level is reduced
many weeks before the onset of the disorder (Levine et al.,
2005). Restoration of the angiogenic balance is critical to
improving and even potentially curing preeclampsia. As
proof, the in vitro removal of sFlt-1 from the placental
condition media of preeclamptic women by immunopre-
cipitation restored theangiogenic imbalanceandpromoted
the capillary-like tube formation similar to normal preg-
nancy (Ahmad and Ahmed, 2004). Furthermore, using the
murine model of sFlt-1-induced preeclampsia, neutraliza-
tion of sFlt-1 belowa critical threshold eliminated the signs
of preeclampsia in the mice (Bergmann et al., 2010). Clin-
ically, the same concept of removal of sFlt-1 to improveHeme oxygenase degrades heme to produce biliverdin, carbon monoxide
(CO), and free iron. Biliverdin is rapidly converted to bilirubin bybiliverdin
reductase (BVR).
preeclampsiawaselegantly tested in severelypreeclamptic
women in whom the extractions of proteins by plasma
apheresis resulted in a one-third reduction in circulating
sFlt-1, accompanied by a decrease in proteinuria and stabi-
lization of maternal blood pressure, leading to an increase
in gestational age (Thadhani et al., 2011). Collectively, these
separate studies do indeed demonstrate that restoration of
the angiogenic balance correlateswith the improvement in
the clinical signs of preeclampsia.
3. Heme oxygenases
Heme oxygenase (Hmox) is the rate-limiting enzyme
responsible for thedegradationofheme in theendoplasmic
reticulum to generate an equimolar amount of biliverdin,
free iron, and carbon monoxide (CO) (Tenhunen et al.,
1969). The pathway also consists of the co-factors, reduced
nicotinamide dinucleotide phosphate (NADPH), molecular
oxygen, and NADPH cytochrome P450 reductase, which,
together with heme oxygenase, induce the catalysis of
heme (Maines, 1988) (Fig. 1). Biliverdin is rapidly reduced
to bilirubin, a potent anti-oxidant, by the cytosolic enzyme
biliverdin reductase. CO is a potent vasodilator and also
has anti-apoptotic properties. Hmoxexists in twomain iso-
forms, Hmox1 andHmox2. The enzymeHmox2 is a 36-kDa
protein that is constitutively expressed at high concentra-
tions in the brain, testis, and vascular endothelium. The
inducible form, Hmox1 is a 32-kDa protein that is widely
distributed in the body, with a high concentration in the
liver and the spleen.
The major site of heme degradation in adult animals is
the spleen, where a markedly elevated activity of Hmox
is observed. In mammalian tissues, Hmox1 is induced by
its substrate heme and also by heavy metals. It is also
known as an oxygen-regulated protein-33 (Murphy et al.,
1991) suggesting that oxygen concentration in tissuesmay
inﬂuence its expression. Indeed, stimuli that cause oxida-
tive stress, such as peroxynitrite, modiﬁed lipids, hypoxia,
hyperoxia, ischemia/reperfusion, hyperthermia, and endo-
toxic shock, upregulate the expression of Hmox1 (Sikorski
et al., 2004). There is mounting evidence for the beneﬁcial
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unctions of Hmox via its products (biliverdin, bilirubin,
arbonmonoxide, free iron),which regulate important bio-
ogical processes including oxidative stress, inﬂammation,
poptosis, and angiogenesis in various conditions (Dulak
t al., 2008). Deﬁciency of Hmox1 in humans results in
evere and persistent endothelial damage, as indicated by
he marked elevation in thrombomodulin and von Wille-
rand factor (Yachie et al., 1999). Decreased expression
f Hmox1 has also been associated with pregnancy dis-
rders, such as recurrent miscarriages (Zenclussen et al.,
006), intrauterine growth retardation (Zhao et al., 2009),
nd preeclampsia (Ahmed et al., 2000). This review will
ocus on the role of Hmox system in pregnancy, speciﬁ-
ally inpreeclampsia,where its beneﬁcial role in improving
he clinical signs of preeclampsia in animal models of
reeclampsia has now been demonstrated by a number of
ndependent laboratories.
.1. Localization of Hmox in the placenta
Factors that trigger the clinical signs of preeclampsia
riginate from the placenta. Conﬁrmation of the presence
f Hmox in the placenta is important to determine its
ole in preeclampsia. Indeed, over the last two decades,
he expression and localization of Hmox1 proteins within
he placenta have been extensively investigated. In the
at placenta (Ihara et al., 1998) and the human placenta
Ahmed et al., 2000; McLean et al., 2000; Lash et al., 2003;
oshiki et al., 2000), Hmox1 and Hmox2 are expressed at
oth the mRNA level and the protein level. Immunohisto-
hemical analysis localized the expression of Hmox to the
yncytiotrophoblast and the vascular endothelium in the
lacenta of uncomplicated pregnancy (Ahmed et al., 2000;
cLean et al., 2000; Lash et al., 2003). Hmox2 is located in
he endothelial cells and smooth muscle cells of the blood
essels of the placental villi (Yoshiki et al., 2000; Ahmed
t al., 2000). Duringdevelopment, the expression ofHmox1
RNA in the placenta was shown to gradually increase in
arallelwith gestational age (Ahmedet al., 2000;Miyagami
t al., 2013). In contrast, Yoshiki and colleagues demon-
trated that the mRNA and protein expressions of Hmox1
n human chorionic villi in the ﬁrst trimester of pregnancy
ere similar to those of term in the placenta of uncom-
licated pregnancy, whereas the expression of Hmox2 is
ncreased in late pregnancy (Yoshiki et al., 2000). Despite
eporting distributional differences, these studies demon-
trate that the Hmox system is present within the placenta
nd is likely to play a functional role during pregnancy.
ndeed, a recent study by Zenclussen’s group showed that
O may act as a key molecule in pregnancy success by
odulatinguterinenatural killer cells,which results inpro-
otion the remodeling maternal spiral arteries (Linzke N,
chumacher A, Woidacki K, Croy BA, Zenclussen AC 2013.
arbon Monoxide Promotes Proliferation of Uterine Natu-
alKillerCells andRemodelingof SpiralArteries inPregnant
ypertensive Heme Oxygenase-1 Mutant Mice. December
3, 2013, doi: 10.1161/HYPERTENSIONAHA.113.02403)..2. Functional role of Hmox in the placenta
Through the production of its protective products (car-
on monoxide, iron, and biliverdin), the Hmox systemImmunology 101–102 (2014) 153–160 155
is able to provide mechanisms for protection during
pregnancy against a variety of physiological threats. Hemo-
proteins are responsible for the transfer of oxygen from
the mother to the fetus during pregnancy and heme is
produced by the trophoblast, the site of exchange of sub-
stances between maternal blood and fetal circulation. The
placental vascular endothelium and syncytiotrophoblasts
are exposed to high concentrations of hemoglobin owing
to their direct contact with fetal and maternal blood. As
has been previously demonstrated, hemoglobin and free
heme can undergo auto-oxidation to produce superoxide
and hydrogen peroxide, which in turn promote the forma-
tion of reactive oxygen species (ROS) and damaging free
radicals (Motterlini et al., 1995). Because of its direct con-
tact with fetal blood, fetal heme is likely to be degraded
in the syncytiotrophoblast by the Hmox system to release
bilirubin and CO in the maternal circulation, hence con-
tributing to fetal vasodilation of the placental villi (Ihara
et al., 1998).
The syncytiotrophoblast is also directly exposed to
maternal blood and to maternal immunological attack
and other inﬂammatory stressors such as tumor necrosis
factor- (TNF-), interferon-, and interleukins. These
inﬂammatory mediators and other stressors may induce
the expression of Hmox1 in the syncytiotrophoblasts to
counteract the injurious effect of inﬂammation on the
placenta and to prevent oxidative injury. Indeed, the
pharmacological induction of Hmox1 in human placental
villous explants was shown to offer placental cytoprotec-
tion (Ahmed et al., 2000). In preeclampsia, this endogenous
protective system could be impaired and it is possible
that the decreased expression or the loss of Hmox activity
might contribute to the maternal endothelial dysfunction
observed.
3.3. Hmox1 negatively regulates anti-angiogenic factors
In recent years, the functional beneﬁt of Hmox in
preeclampsia has gained increasing importance, in particu-
lar, after the publication demonstrating that the adenoviral
overexpression of Hmox-1 or direct exposure to CO
reduce both basal and VEGF-E-stimulated sFlt-1 release
from human umbilical vein endothelial cells (HUVEC),
while siRNA-mediatedHmox1 knockdown increases sFlt-1
release (Cudmore et al., 2007). Another study showed that
the Hmox1 mRNA was decreased in the chorionic villous
(fetal placental cells) sampling at just 11 weeks’ gestation
inwomenwhowent on to developpreeclampsia compared
with normal pregnancies (Farina et al., 2008). Furthermore,
a recent study demonstrated that in samples of villous tro-
phoblasts obtained from women between 6 and 11 weeks’
gestation of elective abortion, the mRNA levels of Hmox1
was signiﬁcantly increased with gestational age, whereas
the mRNA expression of sFlt-1 was signiﬁcantly decreased
with increasing gestational age (Miyagami et al., 2013).
Collectively, these two studies reinforce the theory that
during pregnancy, Hmox1 negatively regulates sFlt-1 and
that the loss of Hmox1 activity early in pregnancy could
be partly responsible for the cascade of events observed
subsequently in preeclamptic pregnancies, such as the
ductive Immunology 101–102 (2014) 153–160
Fig. 2. Unifying preeclampsia model of endothelial dysfunction and
endothelial protection in the amelioration of preeclampsia.
It is the loss of heme oxygenase-1 (Hmox1)/carbon monoxide (CO) activ-
ity,which leads to an increase in soluble Flt-1 (sFlt-1) and soluble Endoglin
(sEng), that causes loss of nitric oxide (NO) bioavailability, giving rise to
endothelial dysfunction and the preeclamptic phenotype. Decrease in CO156 W. Ramma, A. Ahmed / Journal of Repro
elevation in sFlt-1 aswell as the increase in oxidative stress
or inﬂammation (Ahmed, 2011).
Other laboratories have used mice models to demon-
strate the effect of the loss of function of theHmox1 system
on pregnancy. Crossbreds of Hmox1 heterozygote mice
(Hmox1+/−) resulted inHmox1+/− placentas thathadsignif-
icantly lower Hmox1 mRNA and protein levels compared
with wild-type littermates. Additionally, the Hmox1+/−
placentas were smaller than thewild-type placentas. More
importantly, the diastolic blood pressure and plasma sFlt-
1 level were signiﬁcantly elevated in pregnant Hmox1+/−
mice compared with their pregnant wild-type counter-
parts (Zhao et al., 2009). A recent study demonstrated that
the pharmacological inhibition of Hmox-1 by tinmesopor-
phyrin in pregnant rats caused an increase in the maternal
mean arterial blood pressure and a reduction in placen-
tal VEGF (George et al., 2013). These studies support the
hypothesis that a partial deﬁciency in Hmox1 during preg-
nancy is associated with changes in the morphology of the
placenta and the dysregulation in the angiogenic balance
(Zhao et al., 2009; Zhao et al., 2011).
The reduced uterine perfusion pressure (RUPP) hyper-
tension model, in which chronic RUPP leads to endothelial
dysfunction and hypertension in the pregnant rat, has also
been used as a tool to study the preeclamptic syndrome.
Gilbert and colleagues demonstrated that the expression
of Hmox1 in the placenta of the RUPP pregnant rats dur-
ing placental ischemiawas signiﬁcantly reduced compared
with control non-ischemic rat placentas. Interestingly, ele-
vation in both circulating sEng and placental expression of
sEng was observed in these pregnant rats (Gilbert et al.,
2009). To substantiate the beneﬁcial and therapeutic role
of Hmox1 and its metabolites in preeclampsia, the same
group demonstrated that the pharmacological induction
of Hmox1 in this rat model attenuated the elevation in
blood pressure, restored the angiogenic balance, and also
reduced placental oxidative stress in the ischemic pla-
centa (George et al., 2011). Furthermore, in the same
RUPP model, George and colleague demonstrated that
RUPP increased oxidative stress and promoted injury of
the placenta by increasing the phosphorylation of medi-
ators of injury in the placentas of pregnant rats. However,
upon induction of Hmox-1 by cobalt protoporphyrin, an
augmentation in pro-survival mediators (Erk and Stat3)
was observed, resulting in injury attenuation (George and
Arany, 2012).
In addition, a study by Zhou and colleagues demon-
strated that angiotensin receptor-1 autoantibody (AT1-AA)
from preeclamptic women injected into pregnant mice
mediated the release of TNF-, which subsequently
induced the release of circulating sEng and sFlt-1 to impair
placental angiogenesis. Of importance, this study also con-
ﬁrms that the pharmacological induction of Hmox1 by
hemin prevented TNF- from inducing sEng production
in mice and that it also blocked the ability of serum
obtained from pregnant mice injected with preeclamptic
IgG to stimulate sEng production by human endothelial
cells (Zhou et al., 2010). This indicates that the func-
tion of Hmox1 is downstream of AT1-AA-mediated TNF-
signaling to negatively regulate sEng production. The sim-
ilar protective effect of PPAR-gamma in the RUPP modeland a rise in sFlt-1may also exacerbate inﬂammation. Induction ofHmox1
or statins offers therapeutic beneﬁt to patients by inhibiting sFlt-1 and
sEng and stimulating Akt, NO, and CO.
was mediated via the Hmox pathway (McCarthy et al.,
2011). Based on these studies, it is fair to conclude that
the ability of the Hmox pathway to beneﬁcially affect mul-
tiple pathological pathways and restore vascular function
during pregnancy makes it an attractive therapeutic target
for treating preeclampsia (Fig. 2A and B).
3.4. CO and bilirubin in preeclampsia
One of the metabolites of the Hmox system, CO, has
also been implicated in preeclampsia. The source of CO
produced in the body, including in the human placen-
tal chorionic villi, was shown to originate from heme,
primarily through the action of Hmox (Ahmed et al.,
2005). Interestingly, women with preeclampsia have a
signiﬁcantly reduced level of CO in their exhaled breath
compared with those with healthy pregnancies, indicat-
ing decreased Hmox activity (Baum et al., 2000; Kreiser
et al., 2004). Furthermore, smoking during pregnancy
reduces the incidence of preeclampsia, despite being asso-
ciatedwith spontaneous abortion, stillbirth, preterm labor,
fetal growth restriction, and placental abruption (Conde-
Agudelo et al., 1999). Smokers are also known to have
ductive Immunology 101–102 (2014) 153–160 157
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Fig. 3. Schematic diagram of the beneﬁts of heme oxygenase-1 and
statins.
Statin administration not only decreases cholesterol levels, leading to
a decrease in plaque formation, but also induces heme oxygenase-1
(Hmox1) expression, which in turn leads to the subsequent productionW. Ramma, A. Ahmed / Journal of Repro
reduced level of circulating sFlt-1 and increased pla-
ental growth factor (PlGF) (Levine et al., 2006). This
aradoxical effect of smoking on the angiogenic factors
ould be explained by the experimental observation that
xposure to CO reduces endothelial and placental sFlt-
and sEng release (Cudmore et al., 2007). Furthermore,
igarette smoke extract has been shown to induce the
xpression of Hmox1 in placental explants (Sidle et al.,
007) and decrease sFlt-1 release from placental villous
xplants without affecting the placental apoptotic status
Mehendale et al., 2007). Taken together, these stud-
es indicate that CO from cigarette smoke could account
or the reduced incidence of preeclampsia in smokers
hrough the inhibition in the release of sFlt-1 and increase
n PlGF (Farina et al., 2008; Ahmed, 2011; Zhao et al.,
009).
To further emphasize the beneﬁcial role of Hmox and
ts metabolites in preeclampsia, a recent retrospective
bservational study of 50,712 pregnancies, 925 of which
nvolved preeclampsia, demonstrated that low levels of
ilirubin were associated with poor maternal and infant
utcomes in women diagnosed with preeclampsia, indi-
ating that bilirubin may act as an anti-oxidant in this
ondition and thus modify the disease (Breslin et al.,
013).
.5. Therapeutic potential of Hmox
A large amount of evidence has now conﬁrmed that the
eduction of sFlt-1 below a critical threshold is of beneﬁt
o preeclamptic women and those protective factors from
he Hmox pathway could be the way forward in ﬁnding
therapy against preeclampsia. Indeed, agents capable of
ompensating for the deﬁciency or inducing the activity of
he Hmox system to reduce sFlt-1 and sEng may have a
ood therapeutic potential in the treatment of preeclamp-
ia. Based on this concept, Ahmed and co-workers have
nitiated a proof-of-concept clinical trial with pravastatin
alled the StAmP study in the United Kingdom (EudraCT
umber2009-012968-13, clinicaltrialsregister.eu) (Ahmed
nd Williams, 2009). The main objective of the trial is to
etermine if pravastatin will lead to a signiﬁcant reduc-
ion in circulating anti-angiogenic factors in women with
arly-onsetpreeclampsia. This trialwill also reveal theben-
ﬁcial or adverse clinical effects to the mother or the baby
ollowing gestational exposure to pravastatin.
Statins areprimarily used to treat hypercholesterolemia
y inhibiting the enzyme HMG-CoA reductase in the liver,
hereby lowering LDL cholesterol production (Goldstein
nd Brown, 2009). They also exert a protective effect on
ascular endothelial cells (Ludman et al., 2009; Weis et al.,
002). More importantly, statins induce the expression of
mox1 and inhibit the cytokine-mediated release of sFlt-
in cultured placental explants (Cudmore et al., 2007).
ice treated with statins were shown to have an increase
n Hmox activity measured as an elevation in CO release
rom their tissues. Increased levels of plasma antioxidant
ere also observed in the same mice treated. Interest-
ngly, treatment with an Hmox inhibitor, in the presence
f statins, abrogated the increase in antioxidant levels in
he mice, indicating that the Hmox pathway may mediateof carbon monoxide (CO) and bilirubin, which inhibit soluble Flt-1 (sFlt-
1) and soluble Endoglin (sEng). This may be one of the mechanisms by
which statins exert their vasoprotective actions.
the beneﬁcial pleiotropic actions of statins (Muchova et al.,
2007) (Fig. 3).
Statins are currently contraindicated during pregnancy,
although available information regarding the outcome of
human pregnancies during which the fetus was exposed
to statins is limited and inconclusive (Ofori et al., 2007).
In the StAmP trial, pravastatin was chosen because of its
highly hydrophilic characteristic and inability to cross the
placenta frommother to fetus (Hatanaka, 2000;McTaggart
et al., 2001). Several animal studies using the preeclampsia
model over-expressing sFlt-1 have now shown that treat-
mentwithpravastatin signiﬁcantly reducesmaternal sFlt-1
levels and improves vascular reactivity (Costantine et al.,
2010; Fox et al., 2011; Saad et al., 2014). In the RUPP rat
model of preeclampsia, treatment with pravastatin also
reduced oxidative stress and lowered mean arterial blood
pressure in the rats (Bauer et al., 2013). Furthermore, in
a rodent model of preeclampsia using a lentiviral vector-
mediated placenta-speciﬁc expression of sFlt-1 system,
treatment of the mice with pravastatin caused a decrease
in sFlt-1, but more importantly it signiﬁcantly raised the
level of PlGF in the same mice (Kumasawa et al., 2011).
In preeclampsia, the maternal circulating level of PlGF is
decreased well before the onset of the disorder (Levine
et al., 2004, 2005). The administration of PlGF in lentivi-
ral sFlt-1 infected mice depresses the level of sFlt-1 and
ameliorated hypertension, glomerular endotheliosis and
proteinuria in the mice (Kumasawa et al., 2011). These
observations support the idea that pravastatin increased
the level of PlGF and counteracted the effect of sFlt-1,
hence improving preeclampsia-like symptoms. The study
by Kumasawa and co-workers also proved that treat-
ment with pravastatin did not cause any deformity in the
pups (Kumasawa et al., 2011). Although the signiﬁcance
of this decrease in PlGF is unknown it has recently been
shown that the loss of hydrogen sulﬁde (H2S) and the
H2S-producing enzyme cystathionine -lyase (Cth) may
ductive158 W. Ramma, A. Ahmed / Journal of Repro
account for the reduction in PlGF in preeclampsia (Wang
et al., 2013). In another study, Fox and colleagues showed
that pravastatin increased the eNOS protein expression
preferentially in the mice vasculature independent of
cholesterol synthesis inhibition. In addition, they reported
that pravastatin induced Hmox1 expression in the mice
kidney, butnot in the liver (Foxet al., 2011). Taken together,
these studies support the use of pravastatin as a good can-
didate for treating or preventing preeclampsia through its
ability to restore angiogenic balance to promote vascular
health.
3.6. Hmox in other pregnancy disorders
Several studies have also attributed the beneﬁcial role
ofHmox inother pregnancydisorders. Acevedo andAhmed
showed thatHmox1andHmox2were located in thehuman
uteri and that Hmox is central to the successful outcome
of pregnancy through the maintenance of uterine quies-
cence and the prevention of preterm labor (Acevedo and
Ahmed, 1998). Furthermore, the pharmacological inhibi-
tion of Hmox1 in pregnant rats resulted in complete fetal
resorption (Alexandreanu and Lawson, 2002), whereas
adenoviral overexpression of Hmox1was shown to sustain
pregnancy in abortion-pronemice (Zenclussenet al., 2004).
In addition, administrationofpravastatin rescuedplacental
dysfunction and preventedmiscarriages in a spontaneous-
abortion mouse model (Redecha et al., 2009).
3.7. Clinical perspective
This review has outlined the evidence supporting the
notion that activation of the Hmox system by statins could
lead to the alleviation of the signs of preeclampsia and
consequently prolong affected pregnancies. This would
seriously improve outcomes for mothers and babies glob-
ally and reduce the lifelong negative health impacts of
preeclampsia.
Currently, statins are Food and Drug Administration
category X drugs, based on the fact that there are no indica-
tions to warrant the use of statins in pregnancy (no beneﬁt
to outweigh any risk) and because of a small case series on
the teratogenic effects of the original statins in use at the
time (Kazmin et al., 2007; Edison andMuenke, 2004). How-
ever, a recent observational study on the use of statins in
the ﬁrst trimester of pregnancy looked at 288 women and
found no adverse effects (Ofori et al., 2007).
The majority of fetal cholesterol originates from de
novo synthesis (fetus or placenta) rather than from mater-
nal sources. Fetal mutations in the cholesterol synthesis
pathway do not synthesize cholesterol and have very low
concentrations of cholesterol in their blood despite normal
maternal levels, suggesting aminor role ofmaternal exoge-
nous sources (Woollett, 2011, 2005). Thus, any concern
regarding the use of pravastatin by preeclamptic women,
because of its action on maternal cholesterol concentra-
tions, is unfounded. Pravastatin is one of the weakest
inhibitors of cholesterol synthesis and it does not cross
the placenta, which makes the safety of pravastatin more
plausible.Immunology 101–102 (2014) 153–160
Apart from inhibiting the release of sFlt-1 (Cudmore
et al., 2007; Costantine et al., 2010; Fox et al., 2011;
Saad et al., 2014), statins have anti-inﬂammatory and
anti-oxidative properties. They increase the activity of
thioredoxin (Haendeler et al., 2004), superoxide dismutase
(SOD) (Landmesser et al., 2005), and the glutathione perox-
idase (Molcanyiovaet al., 2006) systems. Inaddition, statins
also improve factors that are compromised inpreeclampsia
such as NO bioavailability, VEGF, and endothelial progen-
itor cells (Urbich and Dimmeler, 2005; Cudmore et al.,
2007). The world’s ﬁrst randomized placebo-controlled
trial, StAmP (Statins to Ameliorate Early Onset Preeclamp-
sia), for the use of statins in early-onset preeclampsia
is underway and its outcome will inform obstetricians
whether the use of statins in preeclampsia is viable.
Women destined to develop early onset preeclampsia
could be offered preventive statin therapy or therapies,
which up-regulate the “endogenous cytoprotective path-
ways” like Hmox and Cth. A cheap and widely available
therapyagainstpreeclampsiamay indeedbeon thehorizon
should the StAmP trial prove successful and if a worldwide
randomized controlled trial for the use of pravastatin to
treat preeclampsia is positive. This could reduceworldwide
maternal and infant mortality associated with preeclamp-
sia and would signiﬁcantly move forward the United
Nations Millennium Development Goal (MDG-4, reducing
maternal mortality, and MDG-5, reducing child mortality)
set in 2000 following theMillenniumSummit of the United
Nations.
In order to develop other therapies apart from statins to
tackle preeclampsia, basic research is still needed to elu-
cidate fully the role of Hmox1 and its metabolites. Murine
models do not equate to preeclampsia in women, but they
can replicatemanyof thepreeclampsia symptomsand thus
offer very useful tools for performing proof of principle
experiments to determine the role of speciﬁc genes and
therapies. What is now needed is the use of sophisticated
knockout and tissue-speciﬁc knockdown mouse models
combinedwith further clinically based studies, as has been
the case in the cardiovascular ﬁeld.
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